Clinical trials: Anticoagulants
Healthy Volunteer
Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants
The primary objective of the study is to determine whether aspirin alone or aspirin combined with various doses of rivaroxaban causes subclinical GI blood loss as determined by the HemoQuant assay.
- Trial name
- NCT05546957
- Testing
- Aspirin, rivaroxaban low dose, rivaroxaban high dose
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Healthy
Study of Pharmacodynamic Equivalence of Enoxaparin Rovi to Clexane®, in Healthy Volunteers
To demonstrate the pharmacodynamic (PD) equivalence of enoxaparin Rovi (100 mg/mL) 100-mg SC injection to Clexane® (100 mg/mL) 100-mg SC injection in healthy volunteers.
- Trial name
- NCT03363477
- Testing
- Enoxaparin, Clexane
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Rovi Pharmaceuticals Laboratories
DOAC Eligible Subjects
Direct Oral Anticoagulant Assay Detection & Classification Study for the TEG 6S System
Observational trial to evaluate the effectiveness of the TEG6s DOAC cartridge to detect and classify the presence of DOAC drugs in a subject.
- Trial name
- NCT02798328
- Testing
- TEG6s DOAC Cartridge
- Where
- 4 sites in United States
- Volunteers
- 385 people, healthy volunteers welcome
- Sponsor
- Haemonetics Corporation
Venous Thromboembolism
Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery
The objective of this study is to evaluate the safety and efficacy of DU-176b compared with enoxaparin sodium for the prevention of venous thromboembolism in patients after elective hip fracture surgery.
- Trial name
- NCT01181141
- Testing
- DU-176b (edoxaban), Enoxaparin sodium 20mg
- Where
- Japan
- Volunteers
- 92 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Thrombosis, Cancer
A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer
The purpose of this study is to learn whether apixaban is well-tolerated and acceptable as anticoagulant therapy, when administered to patients with advanced or metastatic cancer and at increased risk for venous thromboembolic…
- Conditions
- Thrombosis, Cancer, Pulmonary Embolism
- Trial name
- NCT00320255
- Testing
- Apixaban
- Where
- 14 sites in United States, Canada
- Volunteers
- 130 people
- Sponsor
- Bristol-Myers Squibb
Stroke
Use of Direct Oral Anticoagulants in UK
Many people who suffer from irregular heartbeats (atrial fibrillation) which might cause stroke, need to take blood thinners to prevent it.
- Trial name
- NCT03119116
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Dabigatran, Apixaban
- Where
- United Kingdom
- Volunteers
- 31,336 people
- Sponsor
- Bayer
Emergency Care for Severe Bleeding While on Anticoagulants
Use of Prothrombin Complex Concentrate in Patients Admitted in Emergency Care Units for Severe Bleeding While Receiving Oral Anticoagulants
The study is assessing the impact of an expert eCRF on the management of severe bleeding in the administration of Prothrombin Complex Concentrate in patients treated with oral anticoagulants and adherence to recommendations or…
- Trial name
- NCT03320603
- Testing
- Expert eCRF, Prothrombin Complex Concentrate
- Where
- 26 sites in France
- Volunteers
- 397 people
- Sponsor
- Octapharma
Healthy Volunteers
A Study in Healthy Participants Investigating Biomarkers After Exposure to Heparin When Heparin is Administered in the Fasted State or After a High-fat Meal. Heparin, a Registered Drug, is an Anticoagulant (Blood Thinner) That Prevents the Formation of Blood Clots.
In this study biomarkers in the blood after exposure to heparin in the fasted state or after a high-fat meal will be investigated.
- Trial name
- NCT05178550
- Testing
- Heparin
- Where
- Netherlands
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Non-valvular Atrial Fibrillation
A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients.
Using mandatory nationwide registries and possibly hospital electronic medical records in Norway, the researchers want to understand how well a group of drugs called "non-vitamin K antagonist oral anticoagulants" (rivaroxaban …
- Trial name
- PROTECT-AF (NCT03715725)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Apixaban (Eliquis), Dabigatran etexilate (Pradaxa)
- Where
- Norway
- Volunteers
- 70,000 people
- Sponsor
- Bayer
Thrombosis, Venous
Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related Surgery
Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common post-operative complication.
- Trial name
- NCT01444612
- Testing
- dalteparin, enoxaparin, fondaparinux
- Volunteers
- 4,068 people
- Sponsor
- GlaxoSmithKline
Atrial Fibrillation, Stroke
An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation
The purpose of this study is to compare the efficacy and safety of rivaroxaban with warfarin for the prevention of blood clots in the brain (referred to as stroke) and blood clots in other parts of the body referred to as…
- Conditions
- Atrial Fibrillation, Stroke, Embolism
- Trial name
- NCT00403767
- Testing
- Rivaroxaban, Warfarin
- Where
- 932 sites in United States, Argentina and 42 more
- Volunteers
- 14,269 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Atrial Fibrillation
Health-related Quality of Life in Patients on Anticoagulants
The present study has been designed to describe the health-related quality of life in patients with non valvular atrial fibrillation who have been prescribed a specific anticoagulant treatment for their non valvular atrial…
- Trial name
- RE-QUOL (NCT03134911)
- Testing
- DOAC or VKA, VKA
- Where
- 39 sites in Spain
- Volunteers
- 535 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation
Patient Characteristics, Treatment Patterns And Incidence Of Events (Discontinuation, Persistence, Key Primary Clinical Outcomes) In NVAF Patients Initiating OAC Therapy In Colombia
The study aim to assess demographic and clinical characteristics , treatment patterns and as exploratory analysis will descriptively assess the time to clinical events of NVAF patients treated with oral anticoagulants (OACs) in…
- Trial name
- NCT04234698
- Where
- Colombia
- Volunteers
- 2,076 people
- Sponsor
- Pfizer
Bleeding
A Multifaceted Intervention to Improve Bleeding Management Among Patients Using Oral Anticoagulants (IMPACT-BLEEDING)
Prospective, cluster randomized trial including expected 168 patients with chronic use of oral anticoagulation (OAC) suffering major bleeding.
- Trial name
- NCT06575517
- Sponsor
- AstraZeneca
Healthy Volunteers
Study to Investigate the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Idarucizumab in Chinese Healthy Male and Female Volunteers Who Had Taken Dabigatran Etexilate and Whose Plasma Concentrations of Dabigatran Were at or Close to Steady State
The primary objective of the trial is to investigate the pharmacokinetics and pharmacodynamics of idarucizumab in Chinese healthy male and female subjects following intravenous administration of idarucizumab followed by…
- Trial name
- NCT03086356
- Testing
- Dabigatran etexilate, Idarucizumab
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Boehringer Ingelheim
Prevention, Venous Thromboembolism
A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty
The objective of this study is to assess the efficacy and safety of DU-176b compared with enoxaparin sodium for the prevention of venous thromboembolism in patients after elective total hip arthroplasty.
- Trial name
- NCT01181167
- Testing
- edoxaban, enoxaparin sodium
- Where
- 2 sites in Japan
- Volunteers
- 610 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Atrial Fibrillation
Study to Evaluate the Use of Direct Oral Anticoagulants in UK Clinical Practice For Patients With a First Stroke Attributable to Nonvalvular Atrial Fibrillation
National Institute of Health and Care Excellence (NICE) guidance recommends anticoagulation for stroke prevention in high risk patients with nonvalvular atrial fibrillation (AF).
- Trial name
- NCT05262322
- Testing
- Edoxaban, Apixaban, Rivaroxaban
- Where
- 8 sites in United Kingdom
- Volunteers
- 234 people
- Sponsor
- Daiichi Sankyo UK Ltd, a Daiichi Sankyo Company
Acute Coronary Syndrome
Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes
The purpose of this study is to determine the safety and tolerability of multiple doses of TAK-442once daily, (QD) or twice daily (BID), in subjects with acute coronary syndrome (unstable angina, myocardial infarction).
- Trial name
- NCT00677053
- Testing
- TAK-442
- Where
- 103 sites in United States, Argentina and 17 more
- Volunteers
- 2,753 people
- Sponsor
- Takeda
Anticoagulant
Evaluation of the Pharmacodynamics of a Heparin With Its Biological Comparator, Intravenous Administration
Pharmacodynamic Study - Phase I Experimental Drug: Porcine sodium heparin, injectable solution - 5,000 IU/mL; Blau Farmacêutica S/A.
- Trial name
- NCT05788900
- Testing
- Heparin
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Blau Farmaceutica S.A.
Heparin-Induced Thrombocytopenia, Thrombosis
Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning)
Primary Objective: To assess the safety of bivalirudin as an alternative anticoagulant therapy for patients with new or previous heparin-induced thrombocytopenia (HIT) / heparin-induced thrombocytopenia and thrombosis syndrome…
- Trial name
- NCT00043940
- Testing
- bivalirudin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- The Medicines Company